ADVANCED AGE is related to considerably larger cancer-specific mortality in males with bone-only metastatic prostate most cancers, in response to a big population-based evaluation of knowledge from the Surveillance, Epidemiology, and Finish Outcomes database.
On this retrospective examine, researchers evaluated 11,098 males identified with bone-only metastatic prostate most cancers between 2010 and 2022 to raised perceive how age influences survival outcomes. Practically half of the cohort (48.2%) have been aged 70 years or older, reflecting the predominance of older sufferers on this illness setting.
Age Impacts Survival in Metastatic Prostate Most cancers
Findings confirmed a transparent and progressive enhance in cancer-specific mortality with advancing age. 5-year mortality charges rose from 50.2% in sufferers youthful than 50 years to 64.8% in these aged 80 years and above (p<0.001). Importantly, this affiliation persevered after adjusting for different medical and demographic variables. Sufferers aged 80 years or older had a 78% larger danger of cancer-specific mortality in comparison with youthful counterparts (subdistribution hazard ratio 1.78; 95% CI: 1.45–2.19).
Past age, a number of further components have been recognized as impartial predictors of poorer outcomes. These included non-Hispanic Black race/ethnicity, single marital standing, elevated prostate-specific antigen ranges, and better tumour grade as outlined by the Worldwide Society of Urological Pathology grading system. These findings spotlight the multifactorial nature of survival disparities on this affected person inhabitants.
Therapy patterns have been additionally related to variations in mortality. Radical prostatectomy was linked to decrease cancer-specific mortality, suggesting a possible survival profit in chosen sufferers. In distinction, radiotherapy and chemotherapy have been related to larger mortality within the total cohort, although this seemingly displays confounding by indication, with these therapies extra generally utilized in sufferers with extra superior or aggressive illness.
In subgroup analyses of sufferers aged 70 years and older, prostate-specific antigen ranges and ISUP grade remained sturdy impartial predictors of mortality, reinforcing their worth in danger stratification amongst older people.
Age and Tumour Grade Form Survival Outcomes
The authors conclude that advancing age is an impartial determinant of worse cancer-specific outcomes in bone-only metastatic prostate most cancers. They emphasise that tumour burden, pathological options, and therapy allocation all contribute to age-related disparities in survival, underscoring the necessity for extra individualised therapy approaches in older sufferers.
Reference
Ozsoy C et al. Superior age will increase cancer-specific mortality in bone-only metastatic prostate most cancers: a SEER evaluation. Sci Rep. 2026;16:13511.
Featured picture: ImagineStock on Adobe Inventory
